PMID- 25473153
OWN - NLM
STAT- MEDLINE
DCOM- 20150903
LR  - 20181113
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 20
IP  - 43
DP  - 2014 Nov 21
TI  - Risk of infections associated with biological treatment in inflammatory bowel 
      disease.
PG  - 16014-9
LID - 10.3748/wjg.v20.i43.16014 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitors are biological agents introduced in 
      the late 1990s for the treatment of different immune-mediated diseases as 
      inflammatory bowel disease, rheumatoid arthritis and psoriasis. The most commonly 
      used TNF-alpha antagonists are infliximab, adalimumab, and certolizumab pegol, and 
      though highly effective in lowering inflammation, the efficacy must be weighed 
      against the potential for adverse events. The treatment-induced immunosuppression 
      is suspected to increase the risk of infections, including the risk of 
      reactivation of latent tuberculosis, as the TNF-alpha cytokine plays an important 
      role in the immune function. In this topic highlight a short overview of the 
      infection risk associated with TNF-alpha inhibiter therapy is outlined with a focus 
      on the overall risk of serious infections, mycobacterial infection and latent 
      viral infections.
FAU - Andersen, Nynne Nyboe
AU  - Andersen NN
AD  - Nynne Nyboe Andersen, Tine Jess, Department of Epidemiology Research, Statens 
      Serum Institut, DK-2300 Copenhagen, Denmark.
FAU - Jess, Tine
AU  - Jess T
AD  - Nynne Nyboe Andersen, Tine Jess, Department of Epidemiology Research, Statens 
      Serum Institut, DK-2300 Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biological Products)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Anti-Inflammatory Agents/*adverse effects
MH  - Biological Products/*adverse effects
MH  - Humans
MH  - *Immunocompromised Host
MH  - Inflammatory Bowel Diseases/diagnosis/*drug therapy/immunology
MH  - Latent Tuberculosis/chemically induced/immunology/microbiology
MH  - Opportunistic Infections/*chemically 
      induced/diagnosis/immunology/microbiology/virology
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Virus Diseases/chemically induced/immunology/virology
PMC - PMC4239487
OTO - NOTNLM
OT  - Biological treatment
OT  - Crohn's disease
OT  - Infections
OT  - Inflammatory bowel disease
OT  - Risk
OT  - Tumor necrosis factor-alpha inhibitors
OT  - Ulcerative colitis
EDAT- 2014/12/05 06:00
MHDA- 2015/09/04 06:00
PMCR- 2014/11/21
CRDT- 2014/12/05 06:00
PHST- 2014/06/19 00:00 [received]
PHST- 2014/07/28 00:00 [revised]
PHST- 2014/09/05 00:00 [accepted]
PHST- 2014/12/05 06:00 [entrez]
PHST- 2014/12/05 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
PHST- 2014/11/21 00:00 [pmc-release]
AID - 10.3748/wjg.v20.i43.16014 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2014 Nov 21;20(43):16014-9. doi: 
      10.3748/wjg.v20.i43.16014.